Shi Shengyi, VP of Sinopharm met with Dr. David Kaslow, VP of PATH and his colleagues, and attended the Sixth Sinopharm-PATH Steering Committee Meeting on May 20, 2016.
In her opening address, VP Shi expressed warm welcome to Dr. Kaslow and his colleagues and sincere thanks for the contribution PATH had made to the development of China National Biotech Group (Sinopharm CNBG) in the past decade. With PATH’s support, Sinopharm CNBG achieved remarkable progress including the first WHO prequalified product in China, JE vaccine, the first six-valent Rotavirus vaccine approved to enter clinical trials worldwide, which systematically drove forward the internationalization of Chinese vaccine industry and opened a new page in the history of international certification and United Nations procurement for Chinese vaccines. VP Shi also expected a wider range of cooperation which would definitely improve well-being for the people in China and beyond.
Dr. Kaslow expressed gratitude to Sinopharm for offering great support to vaccine cooperation. Through ten years’joint work, an effective and smooth strategic cooperation mechanism has been established between the two parties. He was highly proud of what Sinopharm CNBG has accomplished. He also added that PATH and Sinopharm will work together to seek and seize more cooperation opportunities in research and development for drugs, diagnostic reagents and medical devices, as well as in African programme.
Ding Haiyun, vice-director of Department of International Cooperation of Sinopharm , Wu Yonglin, VP of Sinopharm CNBG, Sun Wenjun from Bill & Melinda Gates Foundation, along with the delegation from PATH Global and China, the team from headquarter of Sinopharm CNBG, and related project leaders attended the meeting.